



HOMESTEAD

POST ACUTE

1608 Versailles Road

Lexington, KY 40504

Phone: 859-252-0871

Fax: 859-255-2467

To: McLanahan Hand Care

Date: 8/21/25

From: Elvira T.

Fax: 859-399-6697

Re: M. Brown

No. of Pages _____

Urgent

For Review

Please Comment

Please Reply

Notes:

THE INFORMATION CONTAINED IN THIS FAX IS CONFIDENTIAL AND INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. If the reader of this message is not the intended recipient (or employee or agent responsible for delivering it to the intended recipient), you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us by calling 859-252-0871 and return the original message to us at our expense to this address: Homestead Post Acute 1608 Versailles Road Lexington KY 40504. Thank you for your cooperation.

Brown, Mildred W DOB: 01/31/1934 Unofficial Copy of Medical Record

	Instructions	Start Date
Lidocaine 4 %	1 patch, Transdermal, Every 24 Hours Scheduled, Remove & Discard patch within 12 hours or as directed by MD	Start Date: July 31, 2025

Changes to Medications

	Instructions	Start Date
HYDROcodone-acetaminophen 10-325 MG per tablet Commonly known as: NORCO What changed: <ul style="list-style-type: none">• when to take this• reasons to take this	1 tablet, Oral, Every 4 Hours PRN	

Continue These Medications

	Instructions	Start Date
acetaminophen 325 MG tablet Commonly known as: TYLENOL	650 mg, Oral, Every 8 Hours	
B-12 1000 MCG tablet	1,000 each, Daily	
CALCIUM 1200+D3 PO	1 each, Daily	
cetirizine 10 MG tablet Commonly known as: zyrTEC	TAKE ONE TABLET BY MOUTH DAILY	
diltIAZem CD 240 MG 24 hr capsule Commonly known as: CARDIZEM CD	240 mg, Oral, Daily	
folic acid 1 MG tablet Commonly known as: FOLVITE	1 mg, Oral, Daily	
hydrOXYzine 25 MG tablet Commonly known as: ATARAX	25 mg, Oral, Nightly PRN	
melatonin 5 MG tablet	5 mg, Oral, Nightly PRN	
methocarbamol 500 MG tablet Commonly known as: ROBAXIN	250 mg, Oral, 3 Times Daily PRN	
mirtazapine 7.5 MG tablet Commonly known as: REMERON	7.5 mg, Oral, Nightly	
multivitamin with minerals tablet	1 each, Daily	
omeprazole 20 MG capsule Commonly known as: prilLOSEC	20 mg, Oral, Daily	
ondansetron 4 MG tablet Commonly known as: Zofran	4 mg, Oral, Every 8 Hours PRN	

Brown, Mildred W DOB: 01/31/1934 Unofficial Copy of Medical Record

	Instructions	Start Date
polyethylene glycol 17 g packet Commonly known as: MIRALAX	17 g, Oral, Daily PRN	

Allergies:

Allergen:

- Lisinopril
- Phenobarbital
Blisters
- Tizanidine
- Cymbalta [Duloxetine Hcl]

Reactions:

- Cough
- Other (See Comments)

Hallucinations:

- Anxiety and Hallucinations

Discharge Disposition:

Skilled Nursing Facility (DC - External)

Diet:

Hospital:

Diet Order:

Procedures:

- Diet: Regular/House; Texture: Soft to Chew (NDD 3); Soft to Chew: Ground Meat; Fluid Consistency: Thin (IDDSI 0)

Activity:**Restrictions or Other Recommendations:****CODE STATUS:**

Code Status and Medical Interventions: No CPR (Do Not Attempt to Resuscitate); Limited Support; No intubation (DNI)

Ordered at: 07/24/25 1911

Code Status (Patient has no pulse and is not breathing):

No CPR (Do Not Attempt to Resuscitate)

Medical Interventions (Patient has pulse or is breathing):

Limited Support

Medical Intervention Limits:

No intubation (DNI)

Level Of Support Discussed With:

Patient

Future Appointments

Date	Time	Provider	Department	Center
8/18/2025	2:30 PM	Coleman, Lindsie, APRN	MGE RH WALL	LEX

Additional Instructions for the Follow-ups that You Need to Schedule

Brown, Mildred W DOB: 01/31/1934 Unofficial Copy of Medical Record

Discharge Follow-up with PCP As directed

Currently Documented PCP:

Holestol, Bjorn L, MD

PCP Phone Number:

859-277-5771

Follow Up Details: 1 week after discharged from rehab

Discharge Follow-up with Specified Provider: As directed

with ID/Dr. Miedler

To: with ID/Dr. Miedler

Follow Up Details: per his rec

Andrea L. Lyons, MD

07/30/25

Time Spent on Discharge: I spent 39 minutes on this discharge activity which included: face-to-face encounter with the patient, reviewing the data in the system, coordination of the care with the nursing staff as well as consultants, documentation, and entering orders.

Electronically signed by Lyons, Andrea L, MD at 07/30/25 1130

Routing History

Date/Time	From	To	Method
07/30/25 1130	Lyons, Andrea L, MD	Holestol, Bjorn L, MD	In Basket

ED to Hosp-Admission (Current) on 7/24/2025 Note shared with patient

Additional Details

Note status

Signed

Visit Information

Department

7/24/2025 1:23 PM

BAPTIST HEALTH LEXINGTON 4G

Facility #: 100-00000
Date: Aug 20, 2025
Time: 12:45:05 ET

Homestead Post Acute Progress Notes *NEW*

Facility Code: 30
User: Elvia Taulbee

Primary Physician: All **Progress Note Type:** Physician Progress Note (Narrative) **Effective Date Range:** Effective Time Range: All Created Date Range: All Created Time Range: All Author: All Department: All

Resident Name : Brown, Mildred (10047)

Location : 500-B 523 0

Admission 07/30/2025

Date _____

Date of Birth : 01/31/1934

Medical Record #: 10047

Physician: Deedrauth, Deedraud

Allergies: Itraconazole, Diclofenac, Dexamethasone

Pleurococcus - *N. M. & J. B.* - 17

-Will continue to monitor for declines in strength and make any adjustments as necessary as they may hinder the rehabilitation process.

Need for assistance with personnel etc.

Need for assistance with p
-Continue nursing therapy

-Will continue to monitor for need for additional assistance and make adjustments as necessary.

#Deconditioning/Gait instability - Patient is high risk for functional impairment without therapy and adequate pain control. Patient has high risk for developing contractures, pressure ulcers, poor healing or fall if not receiving adequate therapy and pain control.

#Patient will continue all of their medications per primary care physician.
Patients rehab and medical needs were discussed with nursing staff and therapy.
#Discharge planning: Discharge to the patient's home.

#Discharge planning. Pending therapy progress. Will continue discussion with Therapy team, family and SW.
#Pain: Continue current plan.

#Pain - Continue current pain regimen as above

Patient will continue subacute rehabilitation with as needed PT and OT. PT will work on strengthening, endurance training, neuromotor training, gait training, balance training and stair climbing. OT will work on ADL and functional mobility training.

Advanced Care Plan: Full Code

POA/surrogate decision maker: reviewed as documented in EMR

Major Rehabilitation Goals: Mod I for mobility, ADL and transfers.
Rehabilitation Precautions: Fall

RECORDS REVIEW

I personally reviewed records including acute care hospital, skilled nursing facility, and therapy records. Summarization of the acute care course can be found in the hospital course/HPI section. Discussed case with the primary medical team and/or leadership

DIAGNOSIS (ICD10)

S72141D: Displaced intertrochanteric fracture of right femur, subsequent encounter for closed fracture with routine healing J449: Chronic Obstructive Pulmonary Disease, Unspecified I10: Essential (Primary) Hypertension M6281: Muscle Weakness (Generalized) Z741: Need For Assistance With Personal Care

MIPS

** Document e-signed by Paul Jikaniich, MD on Aug 11, 2025 1:26 PM PDT **

Facility #:**Homestead Post Acute****Facility Code: 30****Date: Aug 20, 2025****Progress Notes *NEW*****User: Elvia Taulbee****Time: 12:45:05 ET**

Primary Physician: All Progress Note Type: Physician Progress Note (Narrative) Effective Date Range: Effective Time Range: All Created Date Range: All Created Time Range: All Author: All Department: All

Resident Name : Brown, Mildred (10047)**Location :** 500-B 523 0**Admission** 07/30/2025**Date :****Date of Birth :** 01/31/1934**Medical Record #:** 10047**Gender:** F**Physician :** Doodnaulh, Davanand**Pharmacy :** Med Care Pharmacy**Allergies :** Lisinopril, PHENobarbital, tiZANidine, Cymbalta**Diagnoses :** No Medical Diagnosis Found**Author:** _api_clalmocity [e-SIGNED]

Skin & Wound Evaluation V7.0

Resident: Brown, Mildred (10047)

Effective Date: 08/12/2025 09:16

Location: 500-B 523 0

Initial Admission: 07/30/2025

Admission: 07/30/2025

Date of Birth: 01/31/1934

Score: NA

Category: NA

Physician: Doodnauth, Devanand

A. Describe

1. Type:

- 1. Abrasion
- 2. Abscess
- 3. Arterial
- 4. Blister
- 5. Bruise
- 6. Burn
- 7. Cancer Lesion
- 8. Diabetic
- 9. Hematoma
- 10. Hidradenitis Suppurativa
- 11. Laceration
- 12. Moisture Associated Skin Damage (MASD)
- 13. Mole
- 14. Open Lesion
- 15. Pressure
- 16. Pressure - Kennedy Terminal Ulcer
- 17. Pressure - Medical Device Related Pressure Injury
- 18. Rash
- 19. Skin Tear
- 20. Surgical
- 21. Venous
- 22. Other

15a. Stage:

- 1. Stage 1: Non-blanchable erythema of intact skin
- 2. Stage 2: Partial-thickness skin loss with exposed dermis
- 3. Stage 3: Full-thickness skin loss
- 4. Stage 4: Full-thickness skin and tissue loss
- 5. Deep Tissue Injury: Persistent non-blanchable deep red, maroon or purple discoloration
- 6. Mucosal Membrane: found on mucous membrane
- 7. Unstageable: Obscured full-thickness skin and tissue loss

15a7a. Due To:

- 1. Slough and/or eschar
- 2. Non-removable device/dressing

22. Location

23. Acquired:

- 1. In-House Acquired
- 2. Present on Admission

24. How long has the wound been present? (wound age when first assessed, after that it is auto calculated):

- 1. New
- 2. Exact Date
- 3. 1 week
- 4. 2 weeks
- 5. 1 month
- 6. 1-3 months
- 7. 3-6 months
- 8. 6-9 months

Skin & Wound Evaluation V7.0

Resident: Brown, Mildred (10047)

- 9. 9-12 months
- 10. 1-2 years
- 11. Over 2 years
- 12. Unknown

24a. Exact Date:

25. Staged by

- 1. N/A
- 2. In-house nursing
- 3. Home Health
- 4. Hospice
- 5. Health Care Provider
- 6. Wound Care Clinic
- 7. Other

B. Wound Measurements

1. Area

 0.5 cm²

2. Length

 1.1 cm

3. Width

 0.7 cm

4. Depth

 Not Applicable

5. Undermining

 Not Applicable

6. Tunneling

 Not Applicable**C. Wound Bed**

- 1. Epithelial
- 2. Granulation
- 3. Slough
- 4. Eschar

4a. % Eschar

- 1. 100% of wound filled
- 2. 90% of wound filled
- 3. 80% of wound filled
- 4. 70% of wound filled
- 5. 60% of wound filled
- 6. 50% of wound filled
- 7. 40% of wound filled
- 8. 30% of wound filled
- 9. 20% of wound filled
- 10. 10% of wound filled
- 11. 0% of wound filled

5. Evidence of Infection

Skin & Wound Evaluation V7.0**Resident:** Brown, Mildred (10047)

- 1. Fever
- 2. Increased drainage
- 3. Increased pain
- 4. Malaise
- 5. Redness/inflammation
- 6. Streaking
- 7. Warmth
- 8. None
- 9. Not applicable

6. Other

- 1. Bleeding
- 2. Bone
- 3. Fibrin
- 4. Gangrene
- 5. Hematoma
- 6. Hypergranulated
- 7. Intact blister
- 8. Islands of epithelium
- 9. Pink or red
- 10. Ruptured blister
- 11. Scab
- 12. Sutured
- 13. None
- 14. Not applicable
- 15. Other

D. Exudate**1. Amount**

- 1. None
- 2. Light
- 3. Moderate
- 4. Heavy

2. Type

- 1. None
- 2. Serous
- 3. Sanguineous/Bloody
- 4. Serosanguineous
- 5. Purulent
- 6. Seropurulent

3. Odor noted after cleansing

- 1. None
- 2. Faint
- 3. Moderate
- 4. Strong

E. Periwound**1. Edges:**

- 1. Attached: Edge appears flush with wound bed or as a sloping edge
- 2. Non-Attached: Edge appears as a cliff
- 3. Rolled Edge (Epibole): Edge appears curled under
- 4. Epithelialization: New, pink to purple, shiny skin tissue

2. Surrounding Tissue:

Skin & Wound Evaluation V7.0

Resident: Brown, Mildred (10047)

- 1. Blanching (whitening of external tissue)
- 2. Blister
- 3. Calloused – Fibrotic or Hyper-keratotic
- 4. Dark reddish brown
- 5. Denuded – loss of epidermis caused by exposure to urine, feces, body fluids, wound exudate or friction.
- 6. Discoloration - black/blue
- 7. Dry/Flaky
- 8. Eczematous
- 9. Erythema: Redness of the skin - may be intense bright red to dark red or purple
- 10. Excoriated: Superficial loss of tissue
- 11. Fragile: Skin that is at risk for breakdown
- 12. Intact: Unbroken skin
- 13. Macerated: Wet, white, waterlogged tissue
- 14. Normal In color
- 15. Scarring
- 16. Other

3. Induration

- 1. None present
- 2. Induration, < 2cm around wound
- 3. Induration 2-4 cm extending < 50% around wound
- 4. Induration 2-4 cm extending > 50% around wound
- 5. Induration > 4 cm in any area around wound

4. Edema

- 1. No swelling or edema
- 2. Non-pitting edema extends < 4cm around wound
- 3. Non-pitting edema extends > 4 cm around wound
- 4. Pitting edema extends < 4 cm around wound
- 5. Crepitus and/or pitting edema extends > 4 cm around wound

5. Periwound Temperature:

- 1. Cool
- 2. Normal
- 3. Warm
- 4. Hot (localized heat)

F. Wound Pain

1. Cognitively Impaired

8. Pain:

0	1	2	3	4	5	6	7	8	9	10
---	---	---	---	---	---	---	---	---	---	----

9. Pain Frequency:

- 1. None
- 2. Intermittent
- 3. At Dressing
- 4. Continuous

10. Notes on Pain:

n/a

G. Orders

1. Goal of Care:

- 1. Heable
- 2. Slow to Heal: wound healing is slow or stalled but stable, little/no deterioration

Skin & Wound Evaluation V7.0

Resident: Brown, Mildred (10047)

3. Monitor/Manage: Wound healing not achievable due to untreatable underlying condition

H. Treatment**1. Dressing appearance:**

- 1. Intact
- 2. Missing
- 3. Dry
- 4. Saturated
- 5. Leaking
- 6. None

2. Cleansing Solution

- 1. Acetic Acid
- 2. Cetrimide
- 3. Chlorhexidine
- 4. Hydrogen peroxide
- 5. Normal Saline
- 6. Povidone Iodine
- 7. Soap & Water
- 8. Sodium hypochlorite
- 9. Sterile Water
- 10. Water
- 11. Generic wound cleanser
- 12. Other
- 13. None

3. Debridement

- 1. Autolytic
- 2. Biologic
- 3. Enzymatic
- 4. Mechanical
- 5. Polyacrylate
- 6. Sharp
- 7. Surgical-outpatient
- 8. None

4. Primary Dressing:

- 1. Antimicrobial
- 2. Antifungal
- 3. Biologic
- 4. Calcium Alginate
- 5. Charcoal
- 6. Clear Acrylic
- 7. Composite Dressing
- 8. Film/Membrane
- 9. Foam
- 10. Hydrocolloid
- 11. Hydrogel
- 12. Hydrophilic Fiber
- 13. Hypertonic
- 14. Negative Pressure Wound Therapy
- 15. Non-Adherent Synthetic
- 16. Pain controlling
- 17. Other
- 18. No dressing applied

Skin & Wound Evaluation V7.0

Resident: Brown, Mildred (10047)

17a. Other, specify

 Skin prep

5. Secondary Dressing:

- 1. Composite
- 2. Compression wrap
- 3. Dry
- 4. Film/Membrane
- 5. Foam
- 6. Hydrocolloid
- 7. Silicone
- 8. Other
- 9. No secondary dressing

6. Modalities

- 1. Electrical stimulation
- 2. Electromagnetic therapy
- 3. Ultrasound mlst
- 4. Other
- 5. None

7. Additional Care

- 1. Air Flow Pad
- 2. Compression
- 3. Cushion
- 4. Customized shoe wear
- 5. Foam Mattress
- 6. Foot cradle
- 7. Heel Suspension/Protection device
- 8. Incontinence management
- 9. Mattress with Pump
- 10. Mobility aid(s) provided
- 11. Moisture barrier
- 12. Moisture Control
- 13. Nutrition/Dietary supplementation
- 14. Padded rails/chair
- 15. Positioning Wedge
- 16. Repositioning device(s)
- 17. Turning/repositioning program
- 18. Other
- 19. None

I. Progress

1. Progress:

- 1. New
- 2. Improving
- 3. Stable
- 4. Stalled
- 5. Deteriorating
- 6. Monitoring
- 7. Resolved

2. Infection

- 1. MD/Provider diagnosed infection
- 2. Suspected Infection
- 3. None

3. Notes:

Skin & Wound Evaluation V7.0

Resident: Brown, Mildred (10047)

 n/a

4. Education:

 n/a

Notifications:

5. Practitioner Notified

5a. Enter name of practitioner notified:

 Dr. Doodnauth6. Resident/Responsible Party Notified:

6a. Enter name of resident/responsible party notified:

 Brenda7. Dietician Notified

7a. Enter the name of dietician notified:

 Haven Kitchens8. Therapy (PT, OT, ST) Notified

Signed By

Andreal Clark, LPN, Unit Coordinator [e-SIGNED]

Signed Date

08/14/2025